NCT03747133Recruiting
SABR for Renal Tumors
Phase II Study: Stereotactic Ablative Radiotherapy for Renal Tumors
Source: ClinicalTrials.gov · Last updated 4 Jun 2026
Brief summary (registry, in English)
Renal Cell Carcinoma (RCC) is the most common type of kidney cancer. The usual treatment for this type of cancer is surgery. Considering the most common patients are an average age of 65 and some are not suitable candiates for surgery, there is great interest in non-surgical alternatives for kidney cancer treatments. This study will investigate the use of Stereotactic Ablative Radiosurgery (SABR) for renal tumors. SABR is a non-invasive alternative, which involves delivery of high doses of radiation to the target, while minimizing the risk of injury to the surrounding organs. Patients will be seen before and end of treatmetn and will be followed at 4 month intervals for up to 2 years. During the follow ups, patients will be asked to complete a quality of life questionnaire and will have standard of care imaging.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- First submitted
- 1 Nov 2018
- Start date
- 1 Nov 2018
- Primary completion date
- Nov 2027
- Lead sponsor
- University Health Network, Toronto
- Diseases
- Kidney cancer
- NCT number
- NCT03747133
What you commit to
- Study type: Interventional
- Planned participants: 90
- From 1 Nov 2018 to the primary completion date, Nov 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Systemic therapy (except endocrine therapy) within 60 days prior to SABR
- Prior abdominal radiotherapy with fields overlap resulting in excessive doses to the involved kidney
Other illness
- Patients with end stage renal failure \> 4(KDOQI guidelines)
- Familial Syndrome: Von Hippel-Lindau disease, Polycystic Kidney Disease, Hereditary Papillary RCC or Tuber Sclerosis
Other
- ≥5 active metastases
Who the study is looking for
- Solid Kidney Mass (primary RCC or metastasis) amenable to SABR ≤6cm
- Histological or radiological diagnosis of renal tumor
- Inoperable: High risk for surgery or declined surgery
- ECOG performance status of 0-3
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Health Network - Princess Margaret Cancer Centre Coordinator of this site? Confirm its status | Toronto | Canada | Recruiting |
Related publications
- Stereotactic Body Radiation Therapy for Renal Tumors: A Prospective Phase 2 Clinical Trial.Int J Radiat Oncol Biol Phys · 2026 · PMID 41290048
This page is information, not medical advice. Discuss any trial with your doctor.